Neratinib News and Research

RSS
I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Researchers test promising new breast cancer drugs

Researchers test promising new breast cancer drugs

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Broad opportunities for covalent drugs

Broad opportunities for covalent drugs

Major study shoots for personalized breast cancer drugs

Major study shoots for personalized breast cancer drugs

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer announces results from studies evaluating neratinib

Pfizer announces results from studies evaluating neratinib

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer to present study findings from its expanded breast cancer portfolio